Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.34 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21374841 | 1.00 | LGALS8 (0.41) | LGALS8SLC2A1MAPK1PYGBLGALS3 | |
| SCHEMBL22334042 | 0.87 | SSTR5 (0.32) | LGALS8 | |
| SCHEMBL19133088 | 0.84 | SLC2A1 (0.33) | SLC2A1 | |
| SCHEMBL19661469 | 0.83 | LGALS8 (0.33) | LGALS8LGALS3 | |
| SCHEMBL12292292 | 0.83 | LGALS8 (0.33) | LGALS8LGALS3 | |
| SCHEMBL20334521 | 0.83 | LGALS8 (0.33) | LGALS8LGALS3 | |
| SCHEMBL23026282 | 0.83 | SLC2A1 (0.48) | LGALS8SLC2A1MAPK1PYGB | |
| SCHEMBL29588366 | 0.83 | SLC2A1 (0.48) | LGALS8SLC2A1MAPK1PYGB | |
| SCHEMBL25597708 | 0.83 | SLC2A1 (0.48) | LGALS8SLC2A1MAPK1PYGB | |
| SCHEMBL22736393 | 0.81 | LGALS8 (0.30) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117745-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING ATXN3 | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| US-20220177883-A1 | Antisense Oligonucleotides Targeting ATXN3 | HOFFMANN-LA ROCHE INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11000600-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210087568-A1 | Modified Guide RNAs for Gene Editing | INTELLIA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210077628-A2 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10822608-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190127735-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127735-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | LGALS8 260/4885SLC2A1 3908/4885MAPK1 4125/4885 |
| US-10822608-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | LGALS8 260/4885SLC2A1 3908/4885MAPK1 4125/4885 |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | LGALS8 2868/4885SLC2A1 3521/4885MAPK1 4816/4885 |
| US-20220177883-A1 | Antisense Oligonucleotides Targeting ATXN3 | ATXN2, ATXN2L, ATXN10 | LGALS8 3732/4885SLC2A1 3926/4885MAPK1 3408/4885 |
| US-20210077628-A2 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | UTRN, CD2BP2, SMN1; SMN2 | LGALS8 2366/4885SLC2A1 3061/4885MAPK1 4796/4885 |
| US-11000600-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | LGALS8 2367/4885SLC2A1 3446/4885MAPK1 4826/4885 |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | LGALS8 2845/4885SLC2A1 3551/4885MAPK1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.